Thanatophoric dysplasia

Thanatophoric dysplasia (TD) is one of the most common lethal skeletal dysplasias, with a name derived from the Greek word 'thanatophoros,' meaning 'death-bearing.' It is a severe short-limbed dwarfism characterized by extreme shortening of the limbs (micromelia), a narrow thorax, relatively large head with frontal bossing, and redundant skin folds along the limbs. The condition is divided into two subtypes: Type I (TD1), which features curved, 'telephone receiver'-shaped femurs and occasional cloverleaf skull deformity, and Type II (TD2), which is characterized by straight femurs and a more consistently present cloverleaf skull (Kleeblattschädel). Both types are caused by heterozygous gain-of-function mutations in the FGFR3 (fibroblast growth factor receptor 3) gene located on chromosome 4p16.3. The condition profoundly affects the skeletal system, with severely shortened long bones, flattened vertebral bodies (platyspondyly), and a markedly small thoracic cage that leads to pulmonary hypoplasia — the primary cause of death. The brain may also be affected, with temporal lobe abnormalities and, in some cases, hydrocephalus. Most affected infants are stillborn or die within hours to days after birth due to respiratory insufficiency caused by the extremely small chest cavity. Rare long-term survivors have been reported, but they typically require intensive respiratory support including tracheostomy and mechanical ventilation, and may develop neurological complications such as brainstem compression and seizures. There is currently no curative treatment for thanatophoric dysplasia. Management is primarily supportive and palliative. Prenatal diagnosis is possible through ultrasound findings of severe limb shortening and a small thorax, often identifiable in the second trimester, and can be confirmed by molecular genetic testing for FGFR3 mutations. Genetic counseling is important for affected families, though the condition almost always arises from de novo mutations, meaning recurrence risk for unaffected parents is very low. Research into FGFR3-targeted therapies is ongoing but has not yet yielded approved treatments for this condition.

Common questions about Thanatophoric dysplasia